Abstract | BACKGROUND:
Olodaterol is a novel long-acting β2-agonist (LABA) with ≥24-h duration of action in preclinical and clinical studies. OBJECTIVE: This Phase II, multicentre, randomised, double-blind, placebo-controlled, parallel-group, dose-finding study evaluated four doses of once-daily olodaterol over 4 weeks in patients with chronic obstructive pulmonary disease ( COPD), based on efficacy, safety and pharmacokinetic parameters. METHODS: Patients received olodaterol inhalation solution or placebo via Respimat® Soft Mist™ inhaler once daily for 4 weeks. Pulmonary function testing was performed pre-dose (trough) and up to 3 or 6 h post-dose, depending on visit. Primary end point was change from baseline in trough forced expiratory volume in 1 s (FEV1) after 4 weeks' treatment. Secondary end points included change from baseline in peak FEV1 and FEV1 area under the curve from 0 to 6 h. RESULTS: 405 patients with COPD were randomised and assigned to treatment. Mean baseline post- bronchodilator FEV1 was 1.50 L (54% predicted). All olodaterol doses provided statistically significant increases in trough FEV1 compared to placebo (2 μg: 0.061 L [p = 0.0233]; 5 μg: 0.097 L [p = 0.0003]; 10 μg: 0.123 L [p < 0.0001]; 20 μg: 0.132 L [p < 0.0001]). A clear dose-response relationship was demonstrated regarding pulmonary function; the two highest olodaterol doses (10 and 20 μg) formed the plateau of the dose-response curve. All olodaterol doses were well tolerated, with no dose-dependent safety effects. CONCLUSION: TRIAL REGISTRATION: ClinicalTrials.gov: NCT00452400.
|
Authors | M Reza Maleki-Yazdi, Ekkehard Beck, Alan L Hamilton, Lawrence Korducki, Paul Koker, Charles Fogarty |
Journal | Respiratory medicine
(Respir Med)
Vol. 109
Issue 5
Pg. 596-605
(May 2015)
ISSN: 1532-3064 [Electronic] England |
PMID | 25829298
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved. |
Chemical References |
- Adrenergic beta-2 Receptor Agonists
- Benzoxazines
- Bronchodilator Agents
- olodaterol
|
Topics |
- Administration, Inhalation
- Adrenergic beta-2 Receptor Agonists
(administration & dosage, adverse effects, pharmacokinetics)
- Aged
- Benzoxazines
(administration & dosage, adverse effects, pharmacokinetics)
- Bronchodilator Agents
(administration & dosage, adverse effects, pharmacokinetics)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Female
- Forced Expiratory Volume
(drug effects)
- Humans
- Male
- Middle Aged
- Pulmonary Disease, Chronic Obstructive
(drug therapy, metabolism)
- Respiratory Function Tests
|